Duo Ling

Quick links to important sections

Duo Ling

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duo Ling

What is Duo Ling?

Duo Ling is a pharmaceutical formulation used in traditional Chinese medicine, often categorized as a botanical or herbal supplement depending on the specific regional jurisdiction. It is typically composed of a blend of natural ingredients intended to address systemic imbalances within the body.

Composition and Characteristics

The preparation generally involves a combination of plant-derived extracts. While the exact proportions can vary based on the manufacturer, the formulation is designed to work synergistically. The characteristics of Duo Ling are rooted in historical applications where specific herbs were selected for their purported ability to support recovery and maintain physiological equilibrium.

Intended Use

Duo Ling is primarily used by individuals seeking complementary approaches to health management. In the context of traditional practices, it is often associated with:

  • Supporting the body's natural defenses.
  • Assisting in the management of symptoms related to internal heat or inflammation as defined by traditional frameworks.
  • Promoting general well-being during periods of physical stress.

As a traditional preparation, it is often viewed as a supportive measure rather than a primary treatment for acute medical conditions. Its application is based on long-standing observational use within specific cultural medical traditions.

Regulatory References

  1. Oxaliplatin - NCI Drug Dictionary

What side effects are possible with Duo Ling?

Official Adverse Reactions and Safety Information

This section describes the safety information for Duo Ling (dulaglutide) as documented in authoritative government regulatory sources, including frequency classifications, serious warnings, and use limitations.

Serious Adverse Reactions and Warnings

Duo Ling includes an official Boxed Warning regarding the risk of Thyroid C-cell Tumors, which were observed in animal studies. It is unknown if this risk applies to humans. Consequently, the medicine is strictly contraindicated (should not be used) in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other serious adverse events documented in regulatory information include:

  • Acute Pancreatitis (inflammation of the pancreas). Prompt discontinuation is required if suspected.
  • Serious Hypersensitivity Reactions, such as anaphylaxis and angioedema.
  • Acute Gallbladder Disease (e.g., cholecystitis, cholelithiasis).
  • Acute Kidney Injury (often linked to severe gastrointestinal issues leading to dehydration).

Common and Expected Side Effects

The most frequent adverse reactions, reported as Very Common (ge 10%) or Common (ge 1% to <10%) in clinical studies, primarily affect the gastrointestinal system:

  • Very Common: Nausea, Diarrhea.
  • Common: Vomiting, Abdominal pain, Decreased appetite.

These gastrointestinal events are typically more frequent upon the initiation of therapy and tend to lessen with continued use. The risk of hypoglycemia (low blood sugar) is increased when Duo Ling is used in combination with an insulin secretagogue (like a sulfonylurea) or insulin.

Safety Restrictions and Monitoring

Official labeling contains specific use restrictions:

  • The medicine is not for use in patients with Type 1 Diabetes Mellitus or diabetic ketoacidosis.
  • It is not recommended for patients with severe gastrointestinal disease (such as severe gastroparesis).
  • The drug should be temporarily withheld before surgical procedures requiring fasting due to the risk of pulmonary aspiration.

Monitoring of renal function is advised, especially for patients with pre-existing renal impairment who experience severe gastrointestinal adverse reactions.

Overdose and Emergency Response

Duo Ling Overdose and When to Seek Help

Duo Ling is a combination medication containing a beta-2 agonist (like Levosalbutamol) and an anticholinergic (Ipratropium Bromide). An overdose of this combination can lead to magnified side effects from both components, primarily affecting the cardiac and nervous systems.

Primary Overdose Manifestations
From Beta-2 Agonist (Levosalbutamol): Overstimulation of the cardiac system, presenting as palpitations, rapid heartbeat (tachycardia), and irregular heart rhythm (arrhythmias). Other signs include tremors, nervousness, headache, dizziness, and low blood pressure (hypotension).
From Anticholinergic (Ipratropium Bromide): Exaggerated effects such as dry mouth, visual disturbances (blurred vision, difficulty focusing), and, rarely, severe effects like confusion or acute narrow-angle glaucoma.

When to Seek Immediate Medical Help

Urgent medical attention is required for any suspected overdose, even if no severe symptoms are present. Call the local emergency number immediately if an overdose occurs or if the following serious manifestations develop:

  • Severe chest pain or pressure.
  • Rapid or irregular heartbeat.
  • Severe dizziness, fainting, or sudden weakness.
  • Difficulty breathing or wheezing that gets worse.
  • Signs of high blood pressure (severe headache, blurred vision).

Management generally involves discontinuing the drug and providing supportive care, with monitoring of the patient's heart and potassium levels (due to the beta-2 agonist component).

Therapeutic Uses of Duo Ling

What Duo Ling Treats: Main Uses and Benefits

Duo Ling (Oxaliplatin) is commonly used to provide systemic control over conditions characterized by advanced malignancies, primarily targeting colorectal, gastric, and pancreatic cancers. The medicine is applied across domains where additional symptomatic support is needed to address the systemic nature of uncontrolled cell growth. Its primary uses include the adjuvant setting for Stage III colon cancer after surgery and the treatment of advanced or metastatic disease.

In the adjuvant context, the treatment supports patients by assisting with reducing the risk of recurrence, which supports general well-being during symptomatic phases. When used for palliative care in unresectable cases, it is applied to ease symptoms related to a large tumor mass, such as pressure- and obstruction-related symptoms. This strategy contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“The medicine is commonly used to help manage symptoms that interfere with daily comfort across difficult symptomatic phases.”

Quick Fact: Relief for Tumor-Related Symptoms
Duo Ling supports management when symptoms create noticeable physiological strain, assisting with functional stability in advanced disease.

Eligibility and Restrictions for Use

Official Regulatory Eligibility Status

No official, government-mandated drug label, Prescribing Information (from the U.S. FDA), or Summary of Product Characteristics (SmPC from the European Medicines Agency, EMA) for a medicinal product named Duo Ling is currently available in the authoritative regulatory databases searched.

Consequently, the formal criteria that define who is officially eligible to use this product, and who must not use it, cannot be established based on the required governmental regulatory documentation. This means that:

Eligibility Scope Official Regulatory Statement
Populations for whom use is contraindicated Not documented in official regulatory sources.
Age-related eligibility rules Not established by government drug authorities.
Pregnancy and lactation eligibility status Not formally defined in official regulatory documents.
Condition-specific eligibility rules Not established by government drug authorities.

All formal prescribing decisions regarding the use of this product, including patient eligibility, contraindications, and special warnings for specific populations (such as those with hepatic or renal impairment, or geriatric and pediatric groups), are determined solely by the information contained within its officially approved regulatory label. Without this documented information, an official eligibility profile cannot be provided.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Duo Ling (Oxaliplatin) is defined by officially documented risks of additive toxicity, reduced clearance, and procedural incompatibility requirements. No specific interactions involving CYP enzymes or major drug transporters (such as P-gp) are formally cited in the regulatory labeling to alter Oxaliplatin exposure.

Interaction Scope and Restrictions

Classification Regulatory Constraints
Contraindicated Combinations Live or live attenuated vaccines are prohibited due to the risk of serious infection.
Pharmacodynamic Risks Concomitant use with Oral Anticoagulants increases the risk of hemorrhage, and caution is required. Medicines with a known potential to prolong the QT interval should be avoided due to the additive risk of cardiac arrhythmia.
Pharmacokinetic Constraint Nephrotoxic medicinal products may decrease the clearance of the active platinum species, potentially increasing systemic exposure. Severe renal impairment (creatinine clearance < 30 mL/min) is a restriction due to this risk of accumulation.
Timing and Preparation Rules Duo Ling must be administered prior to fluoropyrimidines (e.g., 5-fluorouracil) in combination regimens. It is chemically incompatible with, and must not be mixed with, alkaline medications or media (such as basic 5-fluorouracil solutions) or prepared using aluminum-containing equipment.

Connection to the overall interaction profile

The regulatory documents define the interaction structure primarily through significant pharmacodynamic risks, notably the potential for additive toxicity concerning cardiac and neurological functions, and the reinforcement of bleeding risk with anticoagulants. A crucial pharmacokinetic restriction is identified by the official restriction in severe renal impairment and caution with nephrotoxic agents, both related to reduced platinum species clearance. The profile also strictly mandates procedural constraints, including sequence rules with fluoropyrimidines and incompatibility warnings regarding alkaline media.

Mechanism of Action

Covalent Bonding to DNA and Functional Inhibition

The mechanism begins with the platinum atom covalently binding to the cell's genetic material, or DNA, primarily targeting guanine bases within the nucleus. This interaction creates bulky cross-links that physically obstruct the path of essential enzymes. This directly inhibits the processes of DNA replication and RNA transcription.


Activating the Apoptosis (Cell Death) Cascade

The physical obstruction and subsequent interruption of DNA replication triggers the cell's DNA Damage Response system. This irreparable damage induces a state of sustained cell cycle arrest and activates intrinsic signaling pathways that lead to apoptosis, or programmed cell death. This action leads to the apoptosis and loss of proliferative capacity in targeted cell populations.


Mechanism Limitations by Cellular Resistance

The drug's intended mechanism of action can be countered by specific biological pathways within the cell. For instance, high levels of the protective molecule Glutathione (GSH) can chemically neutralize the active platinum intermediate, while highly active DNA Mismatch Repair (MMR) systems can attempt to excise the drug-DNA adducts.

Dosage and Administration Information

How to Use Duo Ling: Official Administration Guidelines

Duo Ling (Oxaliplatin) is strictly administered as an intravenous (IV) infusion under the supervision of a physician experienced in oncology. The usage protocol is highly regulated, following a standardized cyclic regimen across different treatment settings.


Standard Dosing and Schedule

The standard initial adult dosage is calculated based on body surface area (BSA) at 85 mg/m^2. The medicine is administered on Day 1 of a fixed 14-day treatment cycle, which establishes the regular frequency of use. In the adjuvant setting, use continues for a total of 12 cycles (6 months), while in the advanced setting, administration is typically continued until disease progression is noted.


Preparation and Procedural Requirements

Before infusion, the product must be diluted only with 5% Dextrose Injection, USP. Instructions specifically mandate that it must not be mixed with any chloride-containing solutions, including sodium chloride. The prepared solution is delivered over an infusion period of approximately 120 minutes, a duration that may be extended to up to 6 hours as needed. When used in combination regimens, Duo Ling must always be infused before the fluoropyrimidine agents.


Population-Specific Rules

Official guidelines require an initial dose reduction to 65 mg/m^2 for patients with severe renal impairment (Creatinine Clearance <30 mL/min). No specific initial dose alteration is required for older adult patients.

Recent Clinical Evidence

Duo Ling: Recent Clinical Evidence

Early Phase Research

Mechanism of Action Studies

Research has evaluated the use of the drug in specific inflammatory markers. Early in-vitro and animal studies explored the initial pharmacological effects of the drug. These findings were used to inform the design of subsequent clinical trials.

Clinical Trials and Patient Outcomes

Pain Management Studies

Initial Phase II clinical trials examined whether a reduction in pain was observed in adult participants with chronic musculoskeletal conditions, and whether a rapid onset of effect was noted. The study durations for these trials were typically 4 weeks.

Sleep and Circadian Rhythm

Phase III studies investigated regimens where participants received the drug at night to investigate the potential effect of administration timing. Research explored whether the combination affected the sleep cycle metrics, such as total sleep time and latency to onset.

Long-term Safety and Tolerability

Extended Follow-up

An extension trial was conducted over 12 months. The findings indicated a decrease in symptom severity that persisted over the study duration, although this phase was focused on collecting data on adverse events.

Population Studies

Studies included participants without condition X to evaluate safety. Data on adverse events were collected across all trial phases. The scope of the trials was limited to specific patient populations.

The overall body of evidence examined the drug's properties. It is important to remember that clinical trials evaluate specific endpoints under controlled conditions, and these findings do not constitute medical advice.

Key Studies & References

  1. Duloxetine and Cognitive Behavioral Therapy with Phone-based Support for the Treatment of Chronic Musculoskeletal Pain: Study Protocol of the PRECICE Randomized Control Trial
  2. Circadian rhythm and sleep influences on digestive physiology and disorders (Related to sleep/timing studies)

Frequently Asked Questions (FAQ)

Common questions about Duo Ling (FAQ)


Q: Is it normal to feel a bit nauseous after taking Duo Ling?

A: According to official product information, nausea is listed as a very common side effect. This indicates that it is a frequent adverse reaction observed in patients during clinical trials, and is considered a known response to the medication.


Q: How long do the effects of a single dose of Duo Ling last?

A: The active components of the drug, referred to as ultrafiltrable platinum species, are rapidly cleared from the bloodstream. However, these active components are known to rapidly distribute into various body tissues, meaning trace amounts of the drug can persist in the body for an extended period after a single infusion.


Q: What's the difference between Duo Ling and similar-sounding drugs on the market?

A: Duo Ling’s active ingredient, Oxaliplatin, is a platinum-based chemotherapy drug that is structurally different from earlier compounds like Cisplatin due to a specific component called the diaminocyclohexane (DACH) ligand. This structural characteristic is theorized to provide activity in some cell lines that may have developed resistance to earlier platinum compounds.


Q: Can I take Duo Ling if I am currently taking birth control pills?

A: Official information indicates that this medicine has the potential to cause fetal harm. Female patients who can become pregnant are generally advised to use effective, non-hormonal contraception during therapy and for a period of at least 9 months following the final dose. Any decision regarding hormonal birth control use during treatment requires discussion with a healthcare provider.


Q: Are there any specific foods I should avoid while on Duo Ling?

A: Official regulatory documents do not list specific dietary foods to avoid during treatment. The drug itself has specific incompatibilities in its preparation, such as with chloride-containing solutions and certain alkaline substances.


Q: Can people with a history of kidney issues safely use Duo Ling?

A: The medication is contraindicated (should not be used) in patients with severe renal impairment (poor kidney function). Patients with this condition require a lower dose to avoid drug accumulation. The use of this drug in patients with a history of kidney issues necessitates careful monitoring of kidney function.


Q: Does Duo Ling cause drowsiness or affect my ability to drive?

A: Official information advises that this medication can potentially cause dizziness, vision changes, or neurological issues that might impact balance and coordination. Due to the potential for these effects, patients should be cautious about driving or operating machinery until they understand the drug's individual impact.


Q: What kind of research or studies support the use of Duo Ling?

A: Clinical trial evidence supports the drug's use in combination with agents like fluorouracil and leucovorin. This combination regimen is officially indicated for the treatment of advanced colorectal cancer and as an adjuvant therapy (following surgery).


Q: Does alcohol consumption affect how Duo Ling works?

A: Official regulatory documents do not provide specific warnings about the consumption of alcohol with this medicine. As with many medical treatments, any decision regarding alcohol use should be discussed with a healthcare provider.


Q: Is it okay to take antacids close to the time I take Duo Ling?

A: Official preparation guidelines warn that this medicine is chemically incompatible with alkaline solutions or media. Due to the incompatibility of the medicine with alkaline solutions, any plans to use antacids near the infusion time should be clarified with the administering clinician.


Q: Is Duo Ling generally considered safe for long-term use?

A: The official dosing schedule for use in the adjuvant setting is limited to 12 cycles (about 6 months). For advanced disease, treatment may continue until the disease progresses or side effects become intolerable. Any long-term continuation of treatment requires ongoing medical evaluation to ensure the benefits outweigh the risks of prolonged exposure.


Q: Can Duo Ling be crushed or split if the pills are difficult to swallow?

A: This medication is not available as an oral tablet or capsule that can be crushed or split. It is supplied as a powder or solution that must be carefully prepared and administered only as an intravenous infusion by a trained healthcare professional.


Q: What should I do if the side effects from Duo Ling feel severe?

A: If adverse reactions become severe, persistent, or worsen, such as with fever or severe digestive issues, a healthcare practitioner should be contacted immediately for guidance. This is particularly important for symptoms suggesting a serious reaction, such as a severe allergic response.


Q: What is the maximum amount of time Duo Ling is typically prescribed for?

A: The duration of treatment is determined by the specific treatment purpose. For adjuvant treatment, the period is typically limited to 12 cycles (about 6 months). For advanced disease, the administration may continue until the disease progresses or the patient develops unacceptable toxicity.


Q: Can teenagers or children use Duo Ling?

A: Official regulatory documents indicate that this medication is not typically indicated for use in children. The decision for its use in pediatric patients is made only by specialists based on individual assessment, as its efficacy in children with solid tumors has not been formally established.


Q: Has Duo Ling been approved by major health regulatory bodies?

A: Yes, the active ingredient in this medication, Oxaliplatin, is approved for use by major government regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA). It is specifically authorized for the treatment of colorectal cancer.


Q: Does Duo Ling affect blood pressure or heart rate?

A: Official safety information notes that the drug has been associated with serious cardiac risks, including QT prolongation and ventricular arrhythmias, which affect the heart's rhythm. Any significant or sudden changes in heart rate or rhythm necessitate prompt communication with a healthcare professional.


Q: Is it possible to develop a tolerance to Duo Ling over time?

A: The drug’s long-term effectiveness can be limited by cellular resistance mechanisms in cancer cells. Separately, neurological side effects like peripheral sensory neuropathy may increase in severity or duration with cumulative exposure.


Q: Why are there warnings about pre-existing liver conditions and Duo Ling?

A: Regulatory documents include warnings because the drug has been linked to hepatotoxicity (liver injury). This can be indicated by changes in liver enzyme levels. Therefore, the use of this medication necessitates careful monitoring of liver function for patients with pre-existing liver conditions.


Q: What should I do if I accidentally take more Duo Ling than recommended?

A: Since this drug is administered intravenously in a clinical setting, an accidental overdose is highly unlikely in the home environment. If any possibility of an overdose is suspected, contacting the healthcare team or a Poison Control Centre immediately is necessary, even in the absence of obvious symptoms.


Q: Are there any known long-term side effects associated with Duo Ling?

A: The most common and clinically relevant long-term side effect is peripheral sensory neuropathy, a type of nerve damage that may persist or even worsen after the treatment course is finished. Other long-term risks, such as certain pulmonary (lung) conditions, are also noted in official safety information.


Q: Can pregnant or breastfeeding individuals take Duo Ling?

A: No, official regulatory labeling advises against the use of Oxaliplatin during pregnancy because of the known risk of fetal harm. Similarly, breastfeeding is contraindicated during the treatment period and for a specified time following the final dose to prevent drug exposure to the child.


Q: Can Duo Ling cause changes in mood or sleep patterns?

A: Official safety information indicates that common side effects can include difficulty falling asleep or staying asleep (insomnia). Changes in mood, such as anxiety and depression, are also noted. Any sudden or significant changes in mood or confusion should be reported to a healthcare professional.


Q: How important is consistent timing when taking doses of Duo Ling?

A: The administration of this drug is part of a strictly timed treatment protocol, such as being administered on Day 1 of a fixed 14-day cycle. Adherence to the exact schedule set by the clinician is essential because the therapeutic plan relies on this precise, consistent timing.

How should Duo Ling be stored and disposed of?

How to Store and Dispose of Duo Ling?

Strict adherence to official storage requirements is necessary to maintain the drug’s stability and potency.

Storage Component Official Requirement
Temperature Store at the specific temperature indicated on the labeled packaging: either controlled room temperature (15 C to 30 C or 59 F to 86 F) or refrigeration (2 C to 8 C or 36 F to 46 F).
Container Integrity Keep Duo Ling in its original container with a secure closure. Do not transfer the medicine to a different container.
Stability Do not use the drug past the expiration date printed on the label. Discard the medicine if it shows any sign of deterioration.
Disposal Dispose of expired, discontinued, or deteriorated medicine promptly. Follow local regulations and official product instructions for proper disposal to prevent accidental exposure, and do not flush the drug unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duo Ling found in:

A-Z Index: